SHORT ANSWER
FDA quoted four separate boundary statements from the site, then stated that the surrounding copy established intended human use anyway. It cited brand comparisons to Ozempic, Wegovy, and Mounjaro, added two misbranding theories on top of the unapproved-drug theory, and pointed to bacteriostatic water and insulin syringes sold alongside. The letter is fact-specific, but the pattern it describes is common.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / WHAT FDA REVIEWED
One website, two product families, five statutory sections
The letter is dated February 26, 2025 and addressed to USApeptide.com, listed as located in Germany. It opens by stating that FDA “recently reviewed your website at the Internet address www.usapeptide.com” and observed the introduction of “misbranded and unapproved new drugs” into interstate commerce.
Two product families are named: semaglutide and tirzepatide. The opening paragraph cites five sections of the Federal Food, Drug, and Cosmetic Act at once, 301(a), 301(d), 301(k), 503(b), and 505(a), which signals that the letter will stack more than one legal theory. FDA also “requests that www.usapeptide.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers.”
This letter describes what FDA observed on one site on one date. It is an enforcement example, not a rule that applies the same way to every seller.
02 / FOUR DISCLAIMERS
The letter lists the boundary language before setting it aside
This is the letter’s most distinctive passage. FDA quotes four separate statements from the site in a single sentence: “research use only,” “not for human consumption,” “lab purposes only,” and “not intended to diagnose, cure, mitigate, treat or prevent disease.”
The sentence then continues: “evidence obtained from your website establishes that certain products offered for sale by www.usapeptide.com are drugs intended for human use.” The fourth statement is the standard dietary-supplement disclaimer, so the site was running research-use language and supplement-style language side by side. FDA treated all four as statements it had read, and none as controlling.
03 / WHAT GOT QUOTED
Brand names, approval status, and effects in people
FDA introduces the quoted copy as “evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs for human use.” The quotes fall into three patterns.
- Brand equivalence and regulatory status: “Semaglutide, also marketed under the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved injectable for weight loss…” The product names themselves carried a brand: “5mg Tirzepatide (Mounjaro) 5mg.”
- Clinical outcomes: “Semaglutide is a potent once-weekly GLP-1 RA, significantly reducing HbA1c, body weight and systolic blood pressure.”
- Patient framing: “… recently approved in the US to help type 2 diabetes patients better manage blood sugar” and “… stimulates the release of hormones that signal the brain to reduce food intake and increase feelings of fullness.”
Naming an approved product in the listing title told FDA what the seller meant the product to be. The letter later spends two paragraphs explaining what Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are approved for, and that each carries a boxed warning for thyroid C-cell tumors.
04 / THE FIRST THEORY
Drug by intended use, new drug by lack of recognition
The legal chain is the one that appears in most peptide letters. The products are drugs under section 201(g) of the Act because they are “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body.” Intended use is read under 21 CFR 201.128 from labeling, advertising, and the circumstances of sale.
They are new drugs under section 201(p) because they are “not generally recognized as safe and effective for their labeled uses.” With no approved application under section 505 in effect for the specific products sold, FDA states that offering them violates sections 301(d) and 505(a).
The letter is careful on one point: approved semaglutide and tirzepatide exist, but “there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for” the products USApeptide.com was selling. Approval attaches to a specific product from a specific applicant, not to a molecule.
05 / THE SECOND AND THIRD THEORIES
Misbranded twice: no adequate directions, and no prescription
Where many peptide letters stop at unapproved new drug, this one keeps going. Under section 502(f)(1), a drug is misbranded if its labeling “fails to bear adequate directions for use,” meaning directions a layperson could follow safely (21 CFR 201.5). FDA reasons that these are prescription drugs for conditions “not amenable to self-diagnosis and treatment by a layperson,” so adequate lay directions cannot be written at all. Because the products are unapproved, the exemption in 21 CFR 201.115(a) does not apply either. That is a section 301(a) violation.
Separately, under section 503(b)(1), a prescription drug offered without a prescription is misbranded while held for sale, which FDA cites as a section 301(k) violation. The letter states that “by offering the aforementioned drugs without requiring a prescription, www.usapeptide.com jeopardizes patient safety and misbrands the drugs.”
06 / THE SUPPLY BUNDLE
Bacteriostatic water and insulin syringes as context
FDA notes that the products “are intended for injection, which heightens the public health concern,” and then points to two other listings on the same site: “Bacteriostatic Water 20ml Vial” and “10 PACK OF INSULIN SYRINGES ASST. SIZES.”
The letter does not allege those two listings are drugs. It uses them as evidence of how the peptides were meant to be used. Selling the reconstitution water and the syringes beside a research-labeled vial described a route of administration without any product page saying so.
07 / WHAT FDA DEMANDED
Fifteen working days, and a warning about the border
FDA asked for a written response “within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence,” with documentation. A seller that cannot finish in that window is told to state the reason and a completion date. A seller that disagrees is invited to “include your reasoning and any supporting information.”
The letter warns that failure to address the matter “may result in legal action, including, without limitation, seizure and injunction, without further notice.” Because the recipient was outside the United States, FDA adds that products may be “detained or refused admission” at the border and that it may notify regulators in the seller’s home country.
It also tells the seller to review “websites, product labels, and other labeling and promotional materials,” and notes the listed violations may not be all of them.
08 / WHAT TO REVIEW
Three patterns from this letter to check on your own storefront
The letter reads a storefront the way a reviewer would: every surface, together. Three of its findings are worth checking directly.
- Stacked disclaimers. Four boundary statements did not add up to a different result. If the copy around them describes effects in people, more disclaimers do not change what the copy says. Review the copy, not the disclaimer count.
- Brand-name comparisons. Product titles and descriptions that name Ozempic, Wegovy, Mounjaro, or any approved drug tell a reader what the product is meant to substitute for. The same is true of “FDA-approved” language borrowed from the reference product.
- Supply bundles. Reconstitution water, syringes, and needles listed beside the peptides were cited as evidence of intended use. Look at cross-sells, kits, and “frequently bought together” modules, not only the product page.
QUESTIONS
Related questions
Did the supplement-style disclaimer help?
Not in this letter. “Not intended to diagnose, cure, mitigate, treat or prevent disease” was quoted alongside the three research-use statements and set aside with them. It is the standard dietary-supplement disclaimer, and FDA treated it as one more statement on a site whose other copy pointed to human use.
Why does the letter include misbranding when the products were already called unapproved new drugs?
Each theory stands on its own facts. Unapproved new drug turns on intended use and the lack of an approved application. Misbranding under 502(f)(1) turns on whether lay directions can exist, and under 503(b)(1) on whether a prescription was required. Stacking them gives FDA more than one basis for the same conduct.
Would removing the syringes and bacteriostatic water have changed the outcome?
The letter does not say. The supply listings were cited as context, while the brand comparisons and outcome claims were the quoted evidence of intended use. Removing one category of evidence while leaving the rest in place would not have changed what the product copy said.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
Quotes four boundary statements, cites brand-equivalence and outcome claims, and adds 502(f)(1) and 503(b)(1) misbranding theories.
Objective intent shown by labeling, advertising, written statements, and circumstances of distribution.
Section 352(f)(1): a drug is misbranded if its labeling fails to bear adequate directions for use.
Section 353(b)(1): prescription drugs may be dispensed only on a valid prescription; dispensing without one misbrands the drug.